Review article: an unexpected virus-host interaction--the hepatitis C virus-diabetes link (Q36286323)

13 August 2017

1 reference

title

Review article: an unexpected virus-host interaction--the hepatitis C virus-diabetes link (English)

1 reference

13 August 2017

1 reference

1 reference

4

Poynard T

1 reference

13 August 2017

Ratziu V

1

1 reference

13 August 2017

Heurtier A

series ordinal

2

1 reference

13 August 2017

Bonyhay L

series ordinal

3

1 reference

13 August 2017

Giral P

series ordinal

5

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

Alimentary Pharmacology & Therapeutics

13 August 2017

1 reference

13 August 2017

22 Suppl 2

1 reference

13 August 2017

56-60

1 reference

Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease

13 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Hepatitis C virus infection and incident type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Insulin uptake by the human alcoholic cirrhotic liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Transjugular intrahepatic portosystemic shunt (TIPS) augments hyperinsulinemia in patients with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Insulin signalling and the regulation of glucose and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Defects of the insulin receptor substrate (IRS) system in human metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Fibrogenic impact of high serum glucose in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Worsening of steatosis and fibrosis progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02598.X

10.1111/J.1365-2036.2005.02598.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference